uniQure N.V. (QURE)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE).  The investigation concerns whether uniQure and certain of its officers and/or directors have violated federal securities laws.


On December 21, 2020, uniQure disclosed that its hemophilia B gene therapy program, including the Company’s pivotal, Phase III HOPE-B study, had been placed on clinical hold by the U.S. Food and Drug Administration (“FDA”).  Specifically, uniQure advised that the FDA’s “clinical hold was initiated following the submission of a safety report in mid-December relating to a possibly related serious adverse event associated with a preliminary diagnosis of hepatocellular carcinoma (HCC), a form of liver cancer, in one patient in the HOPE-B trial that was treated with etranacogene dezaparvovec (AMT-061) in October 2019.”  On this news, uniQure’s ordinary share price fell $7.44 per share, or 16.19%, to close at $38.51 per share on December 21, 2020.


If you are aware of any facts relating to this investigation, or purchased uniQure shares, you can assist this investigation by visiting contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.